This means that tumor types or patient cases in which the most predictive omics feature for a given targeted therapy is a point mutation are currently beyond the scTherapy approach; for instance, melanomas harboring BRAF-V600E mutation are known to benefit from BRAF inhibitors such as vemurafenib. This evidence concerns the gene BRAF and neoplasm.